These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24327727)

  • 1. β1 integrin: Critical path to antiangiogenic therapy resistance and beyond.
    Jahangiri A; Aghi MK; Carbonell WS
    Cancer Res; 2014 Jan; 74(1):3-7. PubMed ID: 24327727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
    Carbonell WS; DeLay M; Jahangiri A; Park CC; Aghi MK
    Cancer Res; 2013 May; 73(10):3145-54. PubMed ID: 23644530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer.
    Jahangiri A; Nguyen A; Chandra A; Sidorov MK; Yagnik G; Rick J; Han SW; Chen W; Flanigan PM; Schneidman-Duhovny D; Mascharak S; De Lay M; Imber B; Park CC; Matsumoto K; Lu K; Bergers G; Sali A; Weiss WA; Aghi MK
    Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8685-E8694. PubMed ID: 28973887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
    Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
    Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.
    Nigim F; Kiyokawa J; Gurtner A; Kawamura Y; Hua L; Kasper EM; Brastianos PK; Cahill DP; Rabkin SD; Martuza RL; Carbonell WS; Wakimoto H
    Target Oncol; 2019 Aug; 14(4):479-489. PubMed ID: 31301014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells.
    Lin HC; Wu CL; Chen YL; Huang JS; Wong TY; Yuan K
    Clin Oral Investig; 2014 May; 18(4):1277-1284. PubMed ID: 23982443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
    Gyanchandani R; Ortega Alves MV; Myers JN; Kim S
    Mol Cancer Res; 2013 Dec; 11(12):1585-96. PubMed ID: 24092775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
    DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
    Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
    Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
    Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
    Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
    JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
    Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
    Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
    Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
    Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.
    Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
    Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.